Although FST is a reliable tool for the prediction of AKI worsening, as both the meta-analysis by Chen [18] and the review by Coca [19] highlight, debate still exists on the heterogeneity of the studies, the number of enrolled patients, the type of study design, the severity of basal AKI, the role of albumin levels on furosemide sensitivity, the ability of continuous furosemide infusion to increase sensitivity and specificity of the test, as Mariano suggests [20, 21], and the ability of AUC values to define the predictive capacity of a test. The gene discussed is ALB; the disease is acute kidney injury.